drugset / Trial / NCT00076076

The FLASH Study: A Study of Roflumilast Versus Placebo in Patients With Asthma (BY217/M2-023)

NCT00076076

Phase 3 Completed 822 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to confirm the dose of roflumilast to be used for asthma management by comparing the effects of 250 mcg and 500 mcg oral roflumilast with placebo on pulmonary function and asthma symptoms.

Timeline

Start
2003-12
Primary completion
Completion
2005-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Roflumilast Small molecule 250 ug Oral
Subject Roflumilast Small molecule 500 ug Oral

Indications